← Eichor
Condition: Undifferentiated Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Undifferentiated Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Toripalimab With Chemotherapy for Sinus Cancer
Phase 2 · 2 location(s) · Glenn J. Hanna · NCT06940180XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Phase 1 · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06902376Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496Pembrolizumab in Locally Advanced Sinonasal Carcinoma
Phase 2 · 1 location(s) · Istituti Clinici Scientifici Maugeri SpA · NCT05925491Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · 409 location(s) · National Cancer Institute (NCI) · NCT05256225Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions
Phase N/A · 1 location(s) · Centre Francois Baclesse · NCT06612827Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
NA · 1 location(s) · Zhejiang Provincial People's Hospital · NCT07068542DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cance
Phase 2/Phase 3 · 16 location(s) · Cancer Research UK · NCT05768178CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07181720Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patie
Phase 1 · 45 location(s) · BioNTech SE · NCT05142189A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S
Phase 1/Phase 2 · 7 location(s) · St. Jude Children's Research Hospital · NCT06239272Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT04723095A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Phase 2 · 70 location(s) · Fore Biotherapeutics · NCT05503797Sacituzumab govitEcan in THYroid Cancers
Phase 2 · 11 location(s) · Grupo Espanol de Tumores Neuroendocrinos · NCT06235216A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Phase 1 · 16 location(s) · Astellas Pharma Global Development, Inc. · NCT07140016Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
Phase 4 · 8 location(s) · University Medical Center Groningen · NCT05525338Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
Phase 1 · 3 location(s) · City of Hope Medical Center · NCT03975231A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Phase 1 · 10 location(s) · Epkin · NCT06789172Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06176989DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Canc
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770037Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Phase 2 · 1 location(s) · Saint Petersburg State University, Russia · NCT06374602Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Phase 3 · 157 location(s) · Nuvalent Inc. · NCT06765109Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Phase 2 · 137 location(s) · National Cancer Institute (NCI) · NCT05112601[177Lu]Lu-AKIR001 First-in-human Study
EARLY_Phase 1 · 1 location(s) · Karolinska University Hospital · NCT06639191HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Phase 1 · 3 location(s) · M.D. Anderson Cancer Center · NCT03911388NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
Phase 2 · 1 location(s) · Leiden University Medical Center · NCT06079333A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
Phase N/A · 1 location(s) · Peking Union Medical College Hospital · NCT05498064Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
Phase 3 · 1 location(s) · Betta Pharmaceuticals Co., Ltd. · NCT05341583
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.